Apollomics

Apollomics Equity

The The Equity of Apollomics (APLM) as of Oct 17, 2026 is -3.19 M USD. In the previous year, The Equity was 4.86 M USD — a change of -165.54% (lower).

Equity

-3.19 MUSD

YoY

-165.54%

Last updated:

In 2025, Apollomics's equity was -3.19 M USD, a -165.54% increase from the 4.86 M USD equity in the previous year.

The Apollomics Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity
Date
Equity
Jan 1, 2019
-60.72 M USD
Jan 1, 2020
-127.93 M USD
Jan 1, 2021
-212.86 M USD
Jan 1, 2022
-448.12 M USD
Jan 1, 2023
41.23 M USD
Jan 1, 2024
4.86 M USD
Jan 1, 2025
-3.19 M USD
The Apollomics Equity history
YEAREquityYoY
-3.19 MUSD-165.54%
4.86 MUSD-88.20%
41.23 MUSD-109.20%
-448.12 MUSD+110.52%
-212.86 MUSD+66.39%
-127.93 MUSD+110.69%
-60.72 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Apollomics Stock analysis

What does Apollomics do? Apollomics Inc is a clinical-stage biotechnology company based in Foster City, California, operating within the Health Care sector. The company went public via an IPO on November 26, 2021, and is listed under the ticker APLM with ISIN KYG0411D1236. Apollomics focuses on the discovery and development of oncology therapies designed to address unmet medical needs. The company's pipeline includes approximately nine drug candidates, six of which are in clinical development. Its lead program involves vebreltinib (APL-101), a c-Met inhibitor being evaluated in a Phase II multicohort clinical trial for non-small cell lung cancer and other advanced tumors with c-Met alterations. Another key candidate is uproleselan (APL-106), an E-Selectin antagonist under development as an adjunct to standard chemotherapy for acute myeloid leukemia and other hematologic cancers. Apollomics aims to create therapies that can be combined with existing treatments to enhance immune system engagement and target specific molecular pathways in cancer. The company's website is www.apollomicsinc.com. Apollomics is engaged in advancing innovative oncology treatments through clinical research and development. Apollomics is one of the most popular companies on Eulerpool.

Equity Details

Analyzing Apollomics's Equity

Apollomics's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Apollomics's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Apollomics's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Apollomics's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Apollomics’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Apollomics stock

The Equity of Apollomics is -3.19 M USD in 2025.

The Equity of Apollomics changed from 4.86 M USD to -3.19 M USD, representing a -165.54% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The Equity Apollomics since 2006 – with annual values, charts, and detailed analysis.

The Equity's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's Apollomics historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Apollomics

All Key Metrics — Apollomics